Prot #C1071003: MAGNETISMM-3: An Open-Label, Multicenter, Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One Proteasome Inhibitor, One Immunomodulatory Drug and On

Project: Research project

Project Details

StatusActive
Effective start/end date7/21/21 → 7/21/24

Funding

  • Pfizer Inc. (Prot #C1071003)